These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 77062)

  • 21. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
    Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
    Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for combining chemotherapy and hormonal therapy in breast cancer.
    Sertoli MR; Scarsi PG; Rosso R
    J Steroid Biochem; 1985 Dec; 23(6B):1097-103. PubMed ID: 3841574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transient HLA antigenic loss dependent on hormonal state of organism in a healthy woman.
    Májsky A; Jakoubková J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(2):237-41. PubMed ID: 69587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone therapy in inoperable breast cancer.
    Kennedy BJ
    Cancer; 1969 Dec; 24(6):1345-9. PubMed ID: 5353983
    [No Abstract]   [Full Text] [Related]  

  • 25. Metastatic carcinoma to eye from breast; effect of endocrine therapy.
    COGAN DG; KUWABARA T
    AMA Arch Ophthalmol; 1954 Aug; 52(2):240-9. PubMed ID: 13170885
    [No Abstract]   [Full Text] [Related]  

  • 26. [Individual therapy of the metastatic mammary carcinoma (author's transl)].
    Schönfelder M
    Arch Geschwulstforsch; 1980; 50(7):640-6. PubMed ID: 6263208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
    Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M
    Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prolactin and estradiol levels during hormone therapy of breast cancer].
    Grodecka-Gazdecka S; Chwalisz K; Baron J
    Ginekol Pol; 1985 Apr; 56(4):195-201. PubMed ID: 4043797
    [No Abstract]   [Full Text] [Related]  

  • 29. COMBINED ESTROGENIC AND ANDROGENIC HORMONE THERAPY IN ADVANCED BREAST CANCER.
    KENNEDY BJ; BROWN JH
    Cancer; 1965 Apr; 18():431-5. PubMed ID: 14278039
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
    Concha A; Esteban F; Cabrera T; Ruiz-Cabello F; Garrido F
    Semin Cancer Biol; 1991 Feb; 2(1):47-54. PubMed ID: 1912518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of classic and nonclassic HLA class I antigens in uveal melanoma.
    Anastassiou G; Rebmann V; Wagner S; Bornfeld N; Grosse-Wilde H
    Invest Ophthalmol Vis Sci; 2003 May; 44(5):2016-9. PubMed ID: 12714638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal treatment of breast cancer in men. Experiences with antiestrogen Tamoxifen].
    Telhaug R; Fosså SD; Lund G; Børmer O
    Tidsskr Nor Laegeforen; 1982 Dec; 102(34-36):1849-51. PubMed ID: 7170693
    [No Abstract]   [Full Text] [Related]  

  • 33. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
    Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
    J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes of reactivity of rabbit lymphocyte xenoantigens following hormone treatment (author's transl)].
    Májský A
    Allerg Immunol (Leipz); 1980; 26(1):27-30. PubMed ID: 6447444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells.
    Natali PG; Giacomini P; Bigotti A; Imai K; Nicotra MR; Ng AK; Ferrone S
    Cancer Res; 1983 Feb; 43(2):660-8. PubMed ID: 6336658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma.
    Goepel JR; Rees RC; Rogers K; Stoddard CJ; Thomas WE; Shepherd L
    Br J Cancer; 1991 Nov; 64(5):880-3. PubMed ID: 1718386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
    Semiglazov VF; Moiseenko VM; Ivanova OA
    Vopr Onkol; 1986; 32(8):31-4. PubMed ID: 3532535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.